Video

Dr. Slovin on Prostate Cancer Immunotherapy Evolution

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, summarizes the development process of an effective immunotherapy for the treatment men with prostate cancer.

Susan F. Slovin, MD, PhD, an associate member in the Genitourinary Oncology Service at the Memorial Sloan-Kettering Cancer Center, summarizes the development of an effective immunotherapy for the treatment of men with prostate cancer.

The initial phase I/II trials examining immunotherapeutic approaches in prostate cancer were not successful, Slovin states. Many of these agents were tested as single agents and were largely ineffective. However, these early trials successfully demonstrated that an immune response could be elicited in patients with prostate cancer.

Now for the first time, Slovin notes, with sipuleucel-T (Provenge), an immune product vaccine has extended overall survival. By and large, Slovin notes, researchers are still examining the mechanism of action for sipuleucel-T, to further understand how the agent successfully generates a biologic response.

<<<

View coverage from the 2013 IPCC

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Marc-Oliver Grimm, MD
Toni K. Choueiri, MD